Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.37 |
| ▸ | FEN1 | P39748 | 5/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046231 | 0.92 | SYK (0.40) | PTGS2PTGS1SYKNR1H2NR1H3 | |
| SCHEMBL7046168 | 0.91 | PTGS1 (0.40) | PTGS2PTGS1GRM2KMOFFAR1 | |
| SCHEMBL7544751 | 0.85 | PTGS2 (0.45) | PTGS2PTGS1SYKALOX5APFEN1 | |
| SCHEMBL7041595 | 0.85 | PTGS2 (0.47) | PTGS2PTGS1SYKNR1H2NR1H3 | |
| SCHEMBL7537379 | 0.85 | PTGS2 (0.47) | PTGS2PTGS1SYKKMOALOX5AP | |
| SCHEMBL7541582 | 0.84 | DHODH (0.43) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL7044133 | 0.84 | NR1H2 (0.44) | PTGS2PTGS1NR1H2NR1H3KMO | |
| SCHEMBL6723304 | 0.84 | FFAR1 (0.38) | PTGS2PTGS1GRM2KMOFFAR1 | |
| SCHEMBL6746002 | 0.84 | PTGS2 (0.41) | PTGS2PTGS1GRM2KMOFFAR1 | |
| SCHEMBL7048786 | 0.84 | PTGS2 (0.47) | PTGS2PTGS1SYKKMOALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885GRM2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.